52 citations,
October 2012 in “Journal of Dermatological Science”
The document concludes that mouse models are crucial for studying hair biology and that all mutant mice may have hair growth abnormalities that require detailed analysis to identify.
The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactinreceptorinhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactinreceptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The conclusion of the conversation is that the user should consider using treatments such as finasteride, minoxidil, and RU58841 to potentially reverse their hair loss. Other suggestions include using hair loss concealers and maintaining a healthy diet.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.